Gland B2B Business Model and Growth Strategy
Snapshot
13
*
Extensive and Vertically Integrated
Injectables Manufacturing Capabilities
7 Manufacturing
Facilities -
4 Finished Formulation
and 3 API
Greater Control Over
Manufacturing Processes
Consistent Compliance Track Record with
Range of Regulatory Regimes
No Warning Letters
from USFDA Since
Inception of Each
Facility
284 ANDA Filings in
the US (1) (2):
234 Approved; 50
Pending Approval
Diversified B2B-led Model Across Markets
Complemented by a Targeted B2C Model in India
Wide Portfolio of Complex Products Supported
by Internal R&D
Successful Track
Record of Operating
B2B Model with Leading
Pharma Companies
Portfolio of Injectable
Products Across
Therapeutic Areas and
Delivery Systems
Exports to Over 60
Countries(1)
Centralized R&D
Laboratory with Team of
~268 Personnel
Track Record of Growth and Profitability
from a Diversified Revenue Base
FY18-21 (3):
Revenue CAGR: 29%
PAT CAGR:46%
EBITDA margin (4)(5)
FY20 (3): 39% | FY21: 40%
PAT margin (5)
FY20: 28% | FY21: 28%
Note: (1) As of March 31, 2021. (2) Filed by Gland Pharma, along with partners. (3) Based on Financial Information prepared in accordance with Ind AS (4) EBITDA stands for earnings before interest, taxes,
depreciation and amortization which has been arrived at by adding finance expense, depreciation expense, exceptional items and total tax expense to the profit for the year. (5) EBITDA margin = EBITDA / Total
Income; PAT margin = PAT / Total Income.
GLANDView entire presentation